Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 194-209 http://medscipublisher.com/index.php/cge 203 physiological and pathological processes. In colon cancer, exosomal miRNAs have shown significant potential as non-invasive biomarkers for early detection and monitoring. For example, research has identified specific miRNAs within exosomes that are differentially expressed in colon cancer patients compared to healthy individuals. These miRNAs can be detected in blood samples, providing a minimally invasive method for diagnosing colon cancer. A study by Chen et al. (2020) highlighted the diagnostic value of exosomal miR-21 and miR-92a, which were significantly elevated in colon cancer patients. The study demonstrated that these miRNAs could distinguish cancer patients from controls with high sensitivity and specificity, suggesting their potential as early detection biomarkers. Additionally, exosomal miRNAs can provide insights into tumor biology and response to treatment. They can serve as prognostic markers, predicting disease progression and patient outcomes. For instance, elevated levels of exosomal miR-141 have been associated with poor prognosis and shorter overall survival in colon cancer patients. Monitoring changes in exosomal miRNA levels during treatment can help assess therapeutic efficacy and detect early signs of recurrence, enabling timely interventions (Deng et al., 2017). 6.4 Protein biomarkers: CA19-9 and beyond Protein biomarkers are critical tools in the diagnosis and management of colon cancer. Carcinoembryonic antigen (CEA) is the most commonly used protein biomarker, widely recognized for its role in monitoring disease progression and response to therapy. However, other protein biomarkers, such as CA19-9, have also shown promise in enhancing diagnostic accuracy and prognostication. CA19-9, a glycoprotein, is primarily used in pancreatic cancer but has been studied for its potential role in colorectal cancer as well. Elevated CA19-9 levels have been associated with advanced disease stages and poor prognosis in colon cancer patients. Combining CA19-9 with CEA can improve the sensitivity and specificity of diagnostic tests, providing a more comprehensive assessment of the disease (Kneuertz et al., 2015). Recent advancements have identified additional protein biomarkers with potential clinical applications. For example, Cartilage Oligomeric Matrix Protein (COMP) has been shown to be overexpressed in colon cancer tissues and correlates with tumor aggressiveness. Studies have demonstrated that COMP levels can serve as prognostic indicators, with higher levels predicting poorer survival outcomes (Wusterbarth et al., 2021). Furthermore, Chromogranin A (CHGA) has been identified as a novel biomarker for early detection of colon cancer. Research has shown that CHGA levels are significantly higher in colon cancer patients compared to healthy controls, and its measurement can aid in early diagnosis and monitoring of disease recurrence (Zhang et al., 2019). Integrating multiple protein biomarkers into diagnostic panels can enhance the accuracy and reliability of colon cancer detection and management. 7 Challenges and Solutions in Clinical Validation 7.1 Biological and technical variability One of the primary challenges in the clinical validation of non-invasive biomarkers is the inherent biological and technical variability. Biological variability refers to the natural differences in biomarker levels among individuals due to genetic, environmental, and lifestyle factors. This variability can affect the sensitivity and specificity of biomarkers, leading to inconsistencies in diagnostic performance. For instance, factors such as diet, age, sex, and underlying health conditions can influence the levels of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in blood samples, complicating the interpretation of results (Das et al., 2017). Technical variability arises from differences in sample collection, processing, and analysis methods. Variations in blood collection techniques, sample handling, and storage conditions can introduce significant discrepancies in biomarker measurements. Additionally, the sensitivity and specificity of detection technologies, such as next-generation sequencing (NGS) and digital PCR, can vary between laboratories, impacting the reproducibility of results (Vychytilova-Faltejskova et al., 2016).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==